| Active substance | Daratumumab |
| Holder | Janssen-Cilag NV |
| Status | Running |
| Indication | in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 30/06/2025 |